0001543077-18-000002.txt : 20180105
0001543077-18-000002.hdr.sgml : 20180105
20180105122736
ACCESSION NUMBER: 0001543077-18-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180103
FILED AS OF DATE: 20180105
DATE AS OF CHANGE: 20180105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abbey Jeffrey D
CENTRAL INDEX KEY: 0001543077
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35443
FILM NUMBER: 18512717
MAIL ADDRESS:
STREET 1: ARGOS THERAPEUTICS, INC.
STREET 2: 4233 TECHNOLOGY DRIVE
CITY: DURHAM
STATE: NC
ZIP: 27704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001105533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562110007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
BUSINESS PHONE: 9192876300
MAIL ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
FORMER COMPANY:
FORMER CONFORMED NAME: MERIX BIOSCIENCE INC
DATE OF NAME CHANGE: 20000207
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2018-01-03
0
0001105533
ARGOS THERAPEUTICS INC
ARGS
0001543077
Abbey Jeffrey D
ARGOS THERAPEUTICS, INC.
4233 TECHNOLOGY DRIVE
DURHAM
NC
27704
1
1
0
0
President, CEO
Common Stock
2018-01-03
4
S
0
114702
0.1632
D
635033
D
Shares reported represent an amount sold to cover the tax liabilities of the reporting person pursuant to a 10b5-1 sales instruction related to a restricted stock award agreement dated August 30, 2017. Acquisition of the restricted stock was previously reported in Table I of the reporting person's Form 4 on August 31, 2017.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.1581 to $0.1841 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This Form 4 is filed as an amendment to a transaction already disclosed in Table I of the reporting person's Form 4 of 1/5/18. This amendment corrects the range of prices listed in Footnote 2 to Column 4 and makes no other changes.
/s/ Lori R. Harrelson, attorney-in-fact
2018-01-05